What Is Complaint Handling in Medical Device and Pharma QMS?

Complaint handling sits at the intersection of patient safety, post-market surveillance, and regulatory accountability. For medical device manufacturers and pharmaceutical companies, a complaint is not simply a customer service matter. It is a formal quality event with specific documentation, investigation, and reporting obligations that FDA inspectors review on nearly every site visit.

Getting this wrong carries real consequences. In FY2025, complaint handling deficiencies ranked among the top three FDA 483 observations for medical device manufacturers, trailing only CAPA gaps in frequency. FDA Form 483 observations tied to complaints have appeared in recent warning letters to companies including Noah Medical Corporation (April 2025) and Royal Philips (September 2025), where outsourced complaint handling functions lacked adequate oversight and MDR reporting timelines were missed.

This article covers what complaint handling requires under the current regulatory framework, how complaints connect to MDR obligations and CAPA, and where most organizations run into problems.

How the FDA Defines a Complaint

Under 21 CFR Part 820 (the Quality Management System Regulation, or QMSR), a complaint is any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distribution.

That definition is intentionally broad. A call from a hospital biomedical technician saying the device "didn't perform as expected" during a procedure qualifies as a complaint. An email from a distributor noting that packaging arrived damaged qualifies. A sales rep relaying that a customer mentioned difficulty calibrating the device qualifies — even if the customer never contacted the company directly.

The breadth of this definition is where many companies undercount their complaint volume. Organizations that only log formal written complaints from end users routinely miss verbal and field-reported events, which then surface as uncaptured complaints during FDA inspections.

Regulatory Framework: What the Rules Actually Require

Medical Devices — QMSR (21 CFR 820.35)

The FDA's QMSR, which took effect on February 2, 2026, replaced the legacy QSR under 21 CFR Part 820 and harmonized U.S. requirements with ISO 13485:2016. Complaint handling now lives at 21 CFR 820.35, which incorporates ISO 13485 clause 8.2.2 by reference.

The QMSR requires manufacturers to maintain procedures for receiving, reviewing, and evaluating complaints. Specifically, the regulation requires:

• A designated unit with written complaint handling procedures
• An evaluation of every complaint to determine whether it warrants investigation
• Documentation of the reason when a complaint is not investigated
• For complaints that are investigated: documentation of the device name, lot or batch number, date received, name and address of the complainant (if obtainable), nature of the complaint, reply to the complainant (if any), the dates and results of the investigation, and any corrective action taken
• Evaluation of whether the complaint represents an event that must be reported under 21 CFR Part 803 (Medical Device Reporting)

Complaints involving possible malfunction, injury, or death that fall under MDR criteria must be reviewed against reporting thresholds. Under 21 CFR Part 803, manufacturers must submit a 30-day MDR for deaths and serious injuries, and a 5-day report for malfunctions involving a device likely to cause or contribute to serious injury or death if it recurs.

Pharmaceuticals — 21 CFR Part 211 and ICH Q10

For pharmaceutical manufacturers, complaint handling requirements appear in 21 CFR Part 211.198 (for drug manufacturers) and are reinforced by ICH Q10, the pharmaceutical quality system guidance that FDA formally adopted.

21 CFR Part 211.198 requires:

• Written procedures for handling written and oral complaints about drug products
• Designated responsibility for review and evaluation of complaints
• Investigation of any complaint involving the possible failure of a drug product to meet its specifications, or any complaint involving contamination or an unexpected adverse reaction
• Review of complaint records at regular intervals to identify trends that may require corrective action
• Retention of complaint records for at least one year after the expiration date of the batch or lot

ICH Q10 places complaint management within the pharmaceutical quality system's continual improvement framework. Section 3.2 of ICH Q10 lists complaint, deviation, deviation CAPA, and change management processes as core elements of the quality system. The guidance makes clear that trending complaints for signals is expected behavior, not an optional practice.

ISO 13485 Clause 8.2.2

For medical device manufacturers operating under ISO 13485:2016, clause 8.2.2 covers complaint handling as part of feedback from post-production. The standard requires organizations to establish a procedure for handling complaints that includes:

• Determination of whether the event requires reporting to regulatory authorities
• Timely handling of complaints
• Root cause investigation and corrective action where appropriate
• Communication with regulators when required

ISO 13485 also connects complaint handling to post-market surveillance (clause 8.2.1), which requires manufacturers to collect and analyze data from post-production experience, including customer complaints, field service reports, and publicly available data.

The Five Core Steps of an Effective Complaint Handling Process

Regardless of whether a company operates under QMSR, 21 CFR Part 211, or ISO 13485, an effective complaint handling process follows the same logic:

1. Capture and intake. Every complaint must be logged, regardless of source. This includes verbal reports from sales reps, field service technicians, customer support calls, distributor feedback, and social media reports where they can be tied back to a product performance issue. The intake record should capture the date received, product identity, lot or batch, and nature of the event.

2. MDR/regulatory reportability determination. For device manufacturers, every complaint must be evaluated for MDR reportability before investigation begins. The review should be documented. If the complaint does not meet MDR criteria, the reason must be recorded. MDR evaluations have specific clock starts — for death or serious injury events, the 30-day window begins from the date the manufacturer becomes aware, not the date the complaint is formally logged.

3. Investigation decision. The QMS must document whether each complaint warrants full investigation. When the decision is "no investigation required," the reason must be explicitly recorded. FDA inspectors look specifically at not-investigated complaints to check whether companies are using that designation appropriately or using it to suppress inconvenient events.

4. Investigation and documentation. Investigated complaints require documentation of findings, the device or lot involved, any adverse event investigation performed, and any corrective action taken. Investigation timelines should be defined in your procedure. An open-ended complaint investigation with no closure date is a common 483 finding.

5. Trending and CAPA escalation. Individual complaints feed into periodic trending reviews. When trend analysis identifies a pattern — same failure mode, same product family, same market geography — the QMS must have a mechanism to escalate that pattern into a formal CAPA process.

When a Complaint Becomes an MDR

Not every complaint triggers an MDR submission. The MDR threshold under 21 CFR Part 803 requires the event to involve a device that may have caused or contributed to a death or serious injury, or a malfunction that would likely cause or contribute to serious injury if it recurred.

In practice, the MDR evaluation is where complaint files most often fail during inspections. Common failure patterns include:

• Events logged as complaints but MDR evaluation never documented
• MDR evaluation performed but the 30-day clock calculated from the wrong date (investigation close date instead of awareness date)
• Complaints closed without MDR review because they were categorized as "use error" rather than device malfunction, without documented rationale
• Outsourced MDR functions where the contract manufacturer performed the submission but the device manufacturer lacked oversight documentation — the Royal Philips situation in September 2025

Companies that manage MDR evaluations inside their complaint handling workflow — rather than as a separate manual process — have fewer 483 observations in this area. When MDR evaluation is a discrete documented step in the complaint record itself, with a checkbox and a date, it is much harder to miss.

Complaint Trending and Its Role in CAPA

Trending is where complaint handling moves from a reactive documentation task to an actual quality management function.

Under both QMSR and ICH Q10, manufacturers are expected to analyze complaint data at defined intervals to detect signals. That means periodic reviews — typically monthly or quarterly — that look at complaint volume by product, complaint type, failure mode category, market geography, and lot.

A single complaint about a catheter detaching during use may not trigger a CAPA. Fifteen complaints about the same catheter lot over six weeks should. The question FDA asks is whether your trending process would have caught that pattern and whether your procedure defines the threshold at which a trend escalates to formal corrective action.

The risk register for a product should also be updated when trending data reveals failure modes not anticipated during the original risk analysis. Complaint data is a post-market input to risk management under both ISO 13485 and QMSR.

Trending records belong in the audit trail. If you review complaint data monthly and make documented trend decisions, those decisions need to be preserved with timestamps and review signatures. An undocumented verbal review of complaint trends satisfies no one during an FDA inspection.

Where FDA 483 Observations Come From

Based on FDA inspection data and published warning letters from 2024 and 2025, the most frequent complaint handling deficiencies observed by inspectors cluster around five failure patterns:

Undercounting complaints. Companies that train only their quality team to recognize complaints — rather than field service, sales, and customer support — routinely miss events. FDA inspectors specifically ask to interview non-quality employees to test whether the intake training is working.

Inadequate investigation documentation. Investigation records that say "complaint reviewed, no action required" without documenting what was reviewed, what data was examined, and what rationale was used for the no-action determination. The Noah Medical Corporation warning letter in April 2025 cited procedures that described investigation steps but lacked documented evidence those steps were performed.

MDR timing failures. Complaints evaluated for MDR reportability with the clock starting from investigation close rather than date of awareness. FDA calculates MDR timeliness from when the manufacturer had information suggesting the device may have caused the event.

Closed complaints with open CAPA. Complaints marked closed in the system while the associated corrective action is still in progress. The complaint record should remain open or linked until the corrective action is verified effective.

No complaint trending program. Companies that evaluate individual complaints but have no documented periodic trend analysis. This is most often found in smaller manufacturers where QA resources are limited and trending is handled informally.

What a Well-Functioning Complaint Handling System Looks Like

Organizations with low complaint-related 483 observations share a few structural characteristics. Their complaint intake process reaches every customer-facing function, not just quality. Their MDR evaluation is a documented step within the complaint record, with a checkbox and a date, not a downstream process that runs parallel and disconnected.

Their investigation timelines are procedurally defined — typically 30 or 45 days for standard complaints, shorter for potential MDR events — and complaint records do not close without documented investigation outcomes. Trending runs on a fixed calendar with documented outputs that connect directly to the CAPA process when thresholds are crossed.

The QMS captures all of this in one system. When complaint handling, MDR evaluation, CAPA, and trending live in separate spreadsheets or disconnected databases, the linkages break down, and that is exactly what FDA inspectors find.

Complaint Handling in Cloudtheapp

Cloudtheapp's Complaints application within the eQMS platform manages the full complaint handling workflow from intake through MDR evaluation, investigation, and CAPA escalation. All records include a complete, tamper-evident audit trail that meets 21 CFR Part 11 electronic records requirements.

The platform's built-in analytics surface complaint trends by product, lot, failure category, and time period, so trending reviews produce documented outputs rather than informal summaries. When a trend crosses a defined threshold, a CAPA can be initiated directly from the trend record, preserving the link between post-market signal and corrective action.

For teams managing both medical device and pharmaceutical complaint obligations, Cloudtheapp supports configurable workflows that match the specific procedural requirements of QMSR, ISO 13485, and ICH Q10 environments.

If your complaint handling process is built around spreadsheets and manual MDR tracking, request a demo at https://www.cloudtheapp.com/demo/ to see how a purpose-built QMS handles the workflow from first report to closed corrective action.